Clinical Trial Update: Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms [Phase 3]

View source ↗

Summary

The Phase 3 trial evaluating zoledronic acid (zoledronate) with standard therapy versus placebo with standard therapy in asymptomatic recurrent prostate cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zoledronic acid (Zoledronate) (zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED